Immunomedics Financial Statements (IMMU) |
||||||||||
Immunomedicssmart-lab.ru | % | 2019Q4 | 2020Q3 | 2020Q1 | 2020Q2 | 2020Q4 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 27.02.2020 | 06.05.2020 | 06.05.2020 | 05.08.2020 | 05.08.2020 | 05.08.2020 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 0.295 | 0.000 | 0.000 | 20.1 | 20.1 | 40.1 | |||
Operating Income, bln rub | -91.3 | -82.0 | -82.0 | -53.0 | -53.0 | -270.0 | ||||
EBITDA, bln rub | ? | -90.5 | -78.5 | -78.5 | -51.3 | -51.3 | -259.6 | |||
Net profit, bln rub | ? | -99.6 | -93.0 | -93.0 | -66.5 | -66.5 | -319.0 | |||
OCF, bln rub | ? | -92.7 | -71.9 | -71.9 | -30.8 | -30.8 | -205.4 | |||
CAPEX, bln rub | ? | 0.335 | 0.473 | 0.473 | 0.851 | 0.851 | 2.65 | |||
FCF, bln rub | ? | -93.0 | -72.3 | -72.3 | -31.7 | -31.7 | -208.0 | |||
Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
OPEX, bln rub | 16.7 | 82.0 | 82.0 | 71.4 | 71.4 | 306.8 | ||||
Cost of production, bln rub | 74.8 | 0.000 | 0.000 | 1.67 | 1.67 | 3.34 | ||||
R&D, bln rub | 0.000 | 62.4 | 62.4 | 42.6 | 42.6 | 210.0 | ||||
Interest expenses, bln rub | 10.0 | 13.5 | 13.5 | 14.2 | 14.2 | 55.5 | ||||
Assets, bln rub | 671.7 | 594.1 | 594.1 | 1 077 | 1 077 | 1 077 | ||||
Net Assets, bln rub | ? | 268.3 | 186.0 | 186.0 | 593.3 | 593.3 | 593.3 | |||
Debt, bln rub | 262.3 | 271.5 | 271.5 | 272.0 | 272.0 | 272.0 | ||||
Cash, bln rub | 613.2 | 540.6 | 540.6 | 975.5 | 975.5 | 975.5 | ||||
Net debt, bln rub | -350.9 | -269.1 | -269.1 | -703.5 | -703.5 | -703.5 | ||||
Ordinary share price, rub | 21.2 | 13.5 | 13.5 | 35.4 | 35.4 | 87.9 | ||||
Number of ordinary shares, mln | 199.6 | 213.2 | 213.2 | 225.3 | 225.3 | 225.3 | ||||
Market cap, bln rub | 4 224 | 2 875 | 2 875 | 7 985 | 7 985 | 19 797 | ||||
EV, bln rub | ? | 3 873 | 2 605 | 2 605 | 7 281 | 7 281 | 19 093 | |||
Book value, bln rub | 268 | 186 | 186 | 593 | 593 | 593 | ||||
EPS, rub | ? | -0.50 | -0.44 | -0.44 | -0.30 | -0.30 | -1.42 | |||
FCF/share, rub | -0.47 | -0.34 | -0.34 | -0.14 | -0.14 | -0.92 | ||||
BV/share, rub | 1.34 | 0.87 | 0.87 | 2.63 | 2.63 | 2.63 | ||||
EBITDA margin, % | ? | -30 663% | -255.3% | -255.3% | -646.6% | |||||
Net margin, % | ? | -33 765% | -331.1% | -331.1% | -794.6% | |||||
FCF yield, % | ? | -5.43% | -10.5% | -10.5% | -2.61% | -2.61% | -1.05% | |||
ROE, % | ? | -133.2% | -204.3% | -204.3% | -53.8% | -53.8% | -53.8% | |||
ROA, % | ? | -53.2% | -64.0% | -64.0% | -29.6% | -29.6% | -29.6% | |||
P/E | ? | -11.8 | -7.56 | -7.56 | -25.0 | -25.0 | -62.1 | |||
P/FCF | -45.4 | -39.7 | -9.55 | -38.4 | -252.1 | -95.2 | ||||
P/S | ? | 14 318 | 9 744 | 9 744 | 198.9 | 198.9 | 493.1 | |||
P/BV | ? | 15.7 | 15.5 | 15.5 | 13.5 | 13.5 | 33.4 | |||
EV/EBITDA | ? | -12.1 | -7.82 | -7.82 | -28.0 | -28.0 | -73.5 | |||
Debt/EBITDA | 1.09 | 0.81 | 0.81 | 2.71 | 2.71 | 2.71 | ||||
R&D/CAPEX, % | 0.00% | 13 198% | 13 198% | 5 001% | 5 001% | 7 930% | ||||
CAPEX/Revenue, % | 113.6% | 4.24% | 4.24% | 6.60% | ||||||
Immunomedics shareholders |